Dr. Christian S. Hinrichs discusses the future of specialized cell therapies, predicting broader access for community clinics similar to CAR T cell treatments.
GLP-1 RAs are associated with a 62% reduction in 5-year mortality in colon cancer patients, especially those with high obesity. The study's findings remained significant after adjusting for ...
A significant communication gap exists between NMIBC patients and providers, with only 18% having regular discussions about ...
Zipalertinib's NDA submission is based on promising efficacy data from the REZILIENT1 trial, showing a 35.2% ORR and ...
Systemic immunotherapy is emerging as a bladder-sparing option for NMIBC, especially for patients unresponsive to BCG therapy ...
In this discussion, experts review findings from a large real-world dataset comparing clinical outcomes of 2 frontline ...
The FDA approved enfortumab vedotin and pembrolizumab for MIBC, following a priority review of their sBLA for neoadjuvant and ...
Osvyrti and Jubereq are FDA-approved denosumab biosimilars for osteoporosis and cancer-related skeletal events, ...
The FDA has granted full approval to tarlatamab-dlle (Imdelltra) for the treatment of adult patients with extensive stage ...
The process of TIL therapy is complex and requires the coordination of multiple specialties at authorized treatment centers, ...
Zidesamtinib targets ROS1+ NSCLC patients with prior TKI treatment, addressing CNS-penetrant treatment challenges and ...
The second study presented at the SITC meeting focuses on a “next-generation” approach following TIL therapy, utilizing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback